87 related articles for article (PubMed ID: 3488924)
1. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
Bubeník J; Kieler J; Indrová M
Folia Biol (Praha); 1986; 32(3):209-11. PubMed ID: 3488924
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
Símová J; Bubeník J; Voitenok NN; Gren E
Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
Bubeník J; Indrová M; Toulcová A
Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour efficacy of IL-1 and IL-2.
Bubeník J; Indrová M; Holán V
Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
Indrová M; Bubeník J; Toulcová A
Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
[TBL] [Abstract][Full Text] [Related]
6. Active suppression of the proliferative response to interleukin-2 in tumour-bearing mice.
Zajícová A; Holán V
Folia Biol (Praha); 1990; 36(6):301-11. PubMed ID: 2279584
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.
Bubeník J; Perlmann P; Indrová M; Símová J; Jandlová T; Neuwirt J
Cancer Immunol Immunother; 1983; 14(3):205-6. PubMed ID: 6601512
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
10. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens.
Kahan BD; Tanaka T; Pellis NR
J Natl Cancer Inst; 1980 Nov; 65(5):1001-4. PubMed ID: 6159495
[TBL] [Abstract][Full Text] [Related]
13. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of repeated cycles of local IL-2 injections in mice carrying slowly growing tumour grafts.
Símová J; Bubeník J; Indrová M; Bubeníková D; Jandlová T
Folia Biol (Praha); 1993; 39(6):315-22. PubMed ID: 7926162
[TBL] [Abstract][Full Text] [Related]
15. Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines.
Kono K; Petersson M; Ciupitu AM; Wen T; Klein G; Kiessling R
Cancer Res; 1995 Dec; 55(23):5648-55. PubMed ID: 7585649
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of newly induced murine sarcomas.
Shu SY; Rosenberg SA
Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
[TBL] [Abstract][Full Text] [Related]
17. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
